Physician profile
Ahmed S Abuzaid
NPI 1437413895
$76,809.25
in general payments reported to CMS, 2019-2025
14 companies · $24K in 2025
The $24K reported for 2025 was more than what 97% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $254 · 2020: $14.11 · 2021: $569 · 2022: $29K · 2023: $21K · 2024: $2,214 · 2025: $24K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $28K · Consulting Fee: $13K · Food and Beverage: $3,626 · Travel and Lodging: $2,228 · Education: $9.09.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $27,778.17 |
| Consulting Fee | $13,300.00 |
| Food and Beverage | $3,626.22 |
| Travel and Lodging | $2,227.54 |
| Education | $9.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $54,858.47 | 2019-2025 | Camzyos, Eliquis |
| Pfizer INC. | $15,160.09 | 2021-2025 | |
| Bridgebio Pharma, INC. | $3,680.48 | 2025 | Attruby |
| Novartis Pharmaceuticals Corporation | $646.90 | 2022-2025 | |
| Alnylam Pharmaceuticals INC. | $612.15 | 2019-2025 | Amvuttra, Onpattro |
| Celgene Corporation | $600.00 | 2021-2022 | |
| Amgen INC. | $458.77 | 2021-2025 | Repatha |
| Abbott Laboratories | $422.40 | 2019-2025 | Triclip |
| Ge Healthcare | $150.00 | 2025 | |
| Cleerly, INC. | $120.85 | 2025 | Cleerly Labs, Cleerly Ischemia |
| Janssen Pharmaceuticals, INC | $31.15 | 2019 | |
| Astrazeneca Pharmaceuticals Lp | $27.58 | 2025 | Wainua |
| Teva Pharmaceuticals USA, INC. | $20.40 | 2025 | Uzedy |
| Sobi, INC | $20.01 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ahmed Abuzaid listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.